The Number of Platinum Atoms Binding to DNA, RNA and Protein Molecules of HeLa Cells Treated with Cisplatin at Its Mean Lethal Concentration

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1992 May 1

PMID 1618702

Citations 20

Authors

M AKABOSHI

K Kawai

H Maki

K Akuta

Y Ujeno

T Miyahara

Affiliations

Soon will be listed here.

Abstract

HeLa S-3 cells were treated with 195mPt-radiolabeled cis-diamminedichloroplatinum(II) (CDDP) under various conditions, and the relationship between lethal effect and the number of Pt atoms binding to DNA, RNA and proteins was examined. The mean lethal concentrations for the cells treated with CDDP at 37 degrees C for 1, 2 and 3 h were 2.8, 2.0 and 1.1 microgram/ml, respectively. By using identically treated cells, the number of Pt atoms combined with DNA, RNA and protein molecules were determined after fractionation of the cells using the method of Schneider. In this way, the D0 values given as the drug concentration were substituted for the number of Pt atoms combined with each fraction, then the target volumes expressed as the reciprocals of D0 values were calculated for each fraction. The results provide strong support for the idea that DNA is the primary target for cell killing by CDDP, and the target volumes were 5.17 x 10(4), 5.71 x 10(4) and 1.03 x 10(5) nucleotides for 1, 2 and 3 h treated cells, respectively.

Citing Articles

The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry.

Wang J, Tao J, Jia S, Wang M, Jiang H, Du Z Pharmaceuticals (Basel). 2021; 14(2).

PMID: 33572935 PMC: 7911130. DOI: 10.3390/ph14020104.

Interactions of Cisplatin and Daunorubicin at the Chromatin Level.

Niaki E, Van Acker T, Imre L, Nanasi Jr P, Tarapcsak S, Bacso Z Sci Rep. 2020; 10(1):1107.

PMID: 31980698 PMC: 6981277. DOI: 10.1038/s41598-020-57702-7.

Enolate-forming compounds provide protection from platinum neurotoxicity.

Geohagen B, Weiser D, Loeb D, Nordstroem L, LoPachin R Chem Biol Interact. 2020; 317:108961.

PMID: 31978392 PMC: 7069230. DOI: 10.1016/j.cbi.2020.108961.

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy.

Oien D, Garay T, Eckstein S, Chien J Front Pharmacol. 2018; 8:970.

PMID: 29375377 PMC: 5768913. DOI: 10.3389/fphar.2017.00970.

Mapping platinum adducts on yeast ribosomal RNA using high-throughput sequencing.

Plakos K, DeRose V Chem Commun (Camb). 2017; 53(95):12746-12749.

PMID: 29099140 PMC: 5729026. DOI: 10.1039/c7cc06708a.

References

Zwelling L, Kohn K, Ross W, Ewig R, Anderson T . Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum(II). Cancer Res. 1978; 38(6):1762-8. View

Plooy A, van Dijk M, Lohman P . Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 1984; 44(5):2043-51. View

Roberts J, Friedlos F . Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts. Cancer Res. 1987; 47(1):31-6. View

Loehrer P, Einhorn L . Drugs five years later. Cisplatin. Ann Intern Med. 1984; 100(5):704-13. DOI: 10.7326/0003-4819-100-5-704. View

Pascoe J, Roberts J . Interactions between mammalian cell DNA and inorganic platinum compounds. II. Interstrand cross-linking of isolated and cellular DNA by platinum(IV) compounds. Biochem Pharmacol. 1974; 23(9):1345-57. DOI: 10.1016/0006-2952(74)90354-2. View

SCHNEIDER W . Phosphorus compounds in animal tissues; a comparison of methods for the estimation of nucleic acids. J Biol Chem. 2010; 164(2):747-51. View

Zak M, Drobnik J . Effect of cis-dichlorodiamine platinum (II) on the post-irradiation lethality in mice after irradiation with X-rays. Strahlentherapie. 1971; 142(1):112-5. View

Tilby M, JOHNSON C, Knox R, Cordell J, Roberts J, Dean C . Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res. 1991; 51(1):123-9. View

Einhorn L, Donohue J . Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977; 87(3):293-8. DOI: 10.7326/0003-4819-87-3-293. View

10.

Herman T, Teicher B, Chan V, Collins L, Kaufmann M, Loh C . Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo. Cancer Res. 1988; 48(9):2335-41. View

11.

Drobnik J, Horacek P . Specific biological activity of platinum complexes. Contribution to the theory of molecular mechanism. Chem Biol Interact. 1973; 7(4):223-9. DOI: 10.1016/0009-2797(73)90025-2. View

12.

Stewart D, Benjamin R, Luna M, Feun L, Caprioli R, Seifert W . Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol. 1982; 10(1):51-4. DOI: 10.1007/BF00257239. View

13.

Harder H . Renaturation effects of cis and trans platinum II and IV compounds on calf thymus deoxyribonucleic acid. Chem Biol Interact. 1975; 10(1):27-39. DOI: 10.1016/0009-2797(75)90044-7. View

14.

Poirier M, Lippard S, Zwelling L, Ushay H, Kerrigan D, Thill C . Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci U S A. 1982; 79(21):6443-7. PMC: 347142. DOI: 10.1073/pnas.79.21.6443. View

15.

Meyn R, Corry P, Fletcher S, Demetriades M . Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res. 1980; 40(4):1136-9. View

16.

Zwelling L, Anderson T, Kohn K . DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979; 39(2 Pt 1):365-9. View